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 More than 50 years have passed since 
Hans Selye fi rst suggested that the miner-
alocorticoid aldosterone was a proinfl am-
matory and profi brotic agent 1 — actions 
separate from aldosterone ’ s better-known 
eff ects on electrolyte transport. To further 
prove the point and expand this hypoth-
esis, subsequent investigators oft en used 
experimental animal models involving 
treatment with pharmacologic doses of 
mineralocorticoids (aldosterone or deoxy-
corticosterone) given over a period of 
weeks in the presence of sodium loading 
and / or prior renal injury (usually unilat-
eral nephrectomy). Inflammation and 
varying degrees of fi brotic change were 
almost always observed in mineralocorti-
coid-treated animals, especially in the 
heart, arteries, and kidneys. Th e patho-
logic fi ndings induced by aldosterone or 
deoxycorticosterone could be attenuated 
if the animals were also treated with a 
mineralocorticoid receptor (MR) antago-
nist such as spironolactone, even if the 
animals remained hypertensive. Luther 
and his colleagues 2 (this issue) now off er 
an alternative approach; instead of using 
an excess of mineralocorticoids, they took 
away aldosterone as an off ending agent 
and used continuously infused angi-
otensin II to promote tissue injury. Th e 
angiotensin II triggered the release of 
aldosterone from the adrenal gland in 
control mice but not in the genetically 
altered aldosterone-deficient mice. 
Selected animals also received the MR 
antagonist spiro nolactone to determine 
whether the tissue injury was mediated 
through MR activation. 
 In brief, Luther and his associates 2 
found that angiotensin II increased car-
diac mass and fi brotic changes in wild-
type but not in aldosterone-defi cient mice, 
and not in wild-type mice treated with 
spironolactone. Th e authors concluded 
that in the heart, many of the changes 
induced by angiotensin II are probably 
mediated through activation of MR by 
aldosterone. In the aorta, angiotensin II 
increased aortic intima – media thickness 
in wild-type mice but not in aldosterone-
deficient and spironolactone-treated 
wild-type mice. Again, the angiotensin II-
induced eff ects appeared to be mediated 
by aldosterone-activated MR. In the 
kidney studies, the blood urea nitrogen 
increased with angiotensin II infusion 
along with an increase in glomerular 
diameter and some tubular atrophy. In 
this case, aldosterone deficiency did 
not prevent the observed changes, but 
spironolactone did. This finding was 
consistent with MR being activated by 
something other than aldosterone, pos-
sibly endogenous glucocorticoids, since 
their secretion was unaffected in the 
aldosterone-defi cient mice. Th e common 
thread in all of these experiments was that 
pathologic changes were mediated by 
activated MR. Under these experimental 
conditions with the continuous infusion 
of pharmacologic angiotensin II, the 
adrenally released aldosterone alone 
appears to activate MR in vascular tissue, 
but in the kidney, aldosterone and other 
substances can serve as MR-activating 
agents. 
 On the basis of past observations, how 
might we explain the above fi ndings? John 
Funder has referred to a 14 th  century friar 
logician named William of Occam 5 when 
trying to account for variations in steroid 
activation of MR. Occam’s razor (princi-
ple) briefl y is “entities should not be mul-
tiplied unnecessarily” or the simpler 
explanation among competing theories is 
best. Although aldosterone and endog-
enous glucocorticoids such as cortisol and 
corticosterone bind to MR with nearly 
equal affi  nity, 3 only aldosterone consist-
ently activates MR to induce a biologic 
response. Th is receptor selectivity is main-
tained, at least in part, by the actions of 
two enzyme isoforms of 11  -hydroxyster-
oid dehydrogenase (11  -HSD-1 and 11  -
HSD-2). 11  -HSD-1 generally functions 
as a bidirectional enzyme with the direc-
tion dependent on the redox state of the 
cofactor NADP(H). NADP drives the for-
ward dehydrogenase reaction, inactivating 
endogenous glucocorticoids, while 
NADPH promotes the reverse reductase 
reaction, regenerating glucocorticoids 
from their 11-dehydro-metabolites. Th e 
redox state of the cell generally drives the 
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enzyme ’ s direction. 11  -HSD-2 functions 
physiologically only as a dehydrogenase 
and uses NAD as a cofactor. In vascular 
tissue, only endothelial cells appear 
to contain 11  -HSD-2, 4 in very small 
quantities. 11  -HSD-1, which is present 
in both vascular smooth muscle and 
endothelial cells, is bidirectional but tends 
to favor the reductase reaction by approx-
imately three or four to one in cell-intact 
 in vitro experiments. Th is directional pre-
dominance is probably the result of the 
resting redox state within the cell, as men-
tioned. Th us, in vascular tissue, the 11  -
HSD isoforms probably play a limited role 
in determining MR specifi city and activa-
tion ( Figure 1 ). Endogenous glucocorti-
coids bind to vascular MR but do not 
appear able to activate it like aldosterone 
does under normal circumstances. 5 
Endogenous glucocorticoids appear to 
spontaneously activate vascular MR only 
under conditions in which excess reactive 
oxygen species are present (glutathione is 
in the oxidized state), as occurs with tissue 
injury and / or aft er a period of excessive 
sodium dietary intake. 5 
 The structure and functions of 11  -
HSD isoforms in the kidney are quite 
different ( Figure 1 ). Mammalian renal 
proximal tubules contain ample 11  -
HSD-1, but here the enzyme is modifi ed 
and is not bidirectional as in other tissues; 
it functions only as a dehydrogenase. 6 
Collecting duct cells, containing MR, 
express ample 11  -HSD-2, which also 
functions exclusively as a dehydrogenase. 
Th e net eff ect is that both enzyme iso-
forms metabolize endogenous glucocor-
ticoids to their respective inactive 
11-dehydro derivatives and play a major 
role in determining MR specificity for 
aldosterone. When these enzymes are 
inhibited — say, with either exogenous or 
endogenously produced licorice-like 
substances — glucocorticoids can activate 
MR and produce a biologic eff ect identical 
to that of aldosterone. 
 Luther and his associates 2 measured 
mRNA expression of both renal 11  -HSD 
isoforms and noted that the infused angi-
otensin II appeared to have no eff ect in 
either wild-type or aldosterone-defi cient 
mice. Such an analysis is limited, and con-
clusions drawn from that experiment may 
be potentially misleading. Th e ultimate 
physiologic activity of an enzyme is 
dependent on how much of it is present 
(the actual amount of protein, not mes-
sage), its biochemical characteristics ( K m 
and  V max ), the substrate concentrations, 
and the relative availability of the appro-
priate cofactor. Th ere is supporting evi-
dence that angiotensin II does not seem to 
alter the expression of either isoform. 7 
However, angiotensin II may aff ect the 
activity of at least one of the renal 11  -
HSD isoforms. Animals treated with angi-
otensin-converting enzyme inhibitors 
demonstrate an increase in renal dehydro-
genase activity. 8,9 Th is eff ect appears to 
be due to an angiotensin II-mediated 
decrease in 11  -HSD-2 enzymatic activ-
ity. Any local functional decrease in 
11  -HSD-2 would favor MR activation by 
endogenous glucocorticoids. 
 Th e paper by Luther  et al. 2 provides 
further support for therapeutic targeting 
of activated MR to prevent or delay pro-
gression of cardiovascular and renal dis-
ease. The net biologic effects of both 
angiotensin II and aldosterone are prob-
ably mediated via activated MR. Although 
aldosterone has been the most obvious 
ligand for activating MR, it now is becom-
ing clear that other agents, such as corti-
sol in humans and corticosterone in 
rodents, play this role under certain cir-
cumstances. Excess release of reactive 
oxygen species and changes in the redox 
state within target cells caused by prior 
injury, high-salt diet, and / or other 
hormonal agents all may affect the 
MR-activating process. 
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 Figure 1  |  MR selectivity for activation appears to be tissue dependent. Both vascular and 
renal tissue MRs respond to aldosterone, but the MR activation in vascular tissue by endogenous 
glucocorticoids such as cortisol or corticosterone is more related to the presence of reactive 
oxygen species (oxidized glutathione) and is less regulated by 11  -HSD. In the kidney, the activity 
of both renal 11  -HSD isoforms clearly determines whether or not MR is activated by endogenous 
glucocorticoids. 11  -HSD, 11  -hydroxysteroid dehydrogenase; MR, mineralocorticoid receptor.  
